Global drug manufacturers are deploying record capital to eliminate production bottlenecks for metabolic therapies, as current manufacturing capabilities fail to meet surging global clinical demand.
Facility Scale-Up
Capital allocations for specialized sterile fill-finish sites have doubled over the past 12 months. Contract development and manufacturing organizations (CDMOs) report full capacity utilization through 2026.
Payer Coverage Dynamics
As supply constraints ease, focus is shifting to corporate and public health payer coverage negotiations. Employers are implementing stricter prior authorization requirements to manage expanding prescription cost budgets.